Damora Therapeutics Inc
damoratx.comWhat Do They Do?
Develops antibody drug candidates targeting mutant calreticulin for people with blood and bone marrow disorders, including essential thrombocythemia and myelofibrosis.
10-K for FY2025, filed Mar 19, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 19, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$31.2MView ↗
- ▲ +807% (Loss)
- vs −$3.4M in Q2 FY2025
-
May 4, 2026
The CFO ceased serving
Lori Firmani ceased serving as CFO; Brian Burkavage became principal financial officer and principal accounting officer.
Sources
8-K, filed May 4, 2026
On April 28, 2026, the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May…View ↗
-
Apr 20, 2026
Changed its independent auditor
EY Denmark was dismissed and EY US was engaged, both effective immediately.
Sources
8-K, filed Apr 20, 2026
On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a…View ↗
-
Mar 23, 2026
Appointed a new chief executive
Jennifer Jarrett became president and CEO, succeeding Sherwin Sattarzadeh as principal executive officer.
Sources
8-K, filed Mar 23, 2026
The Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) appointed Jennifer Jarrett as President and Chief…View ↗
Who Do They Compete With?
Competes with Incyte, Janssen Pharmaceuticals, Meiji Seika Pharma, Prelude Therapeutics, Alethio Therapeutics, PharmaEssentia, Merck &, Novartis, Geron, and Kartos Therapeutics
10-K for FY2025, filed Mar 19, 2026We are aware of several companies with product candidates in development for the treatment of patients with mutCALR-driven MPNs, including…View ↗
Loading...
